Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation

Annales d'Endocrinologie

Volumn 68, Issue 1, 2007, Pages 21-27

  Vantyghem, M C ^a   Marcelli Tourvielle, S ^a   Pattou, F ^a   Noel C ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

cell; Calcineurins inhibitors; Cyclosporine; Immunosuppressive drugs; Insulin secretion; mTOR inhibitors; Mycophenolate; Sirolimus; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS;

ANAMNESIS; B LYMPHOCYTE; CELL TYPE; CLINICAL TRIAL; DEMOGRAPHY; DISORDERS OF CARBOHYDRATE METABOLISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INHIBITION; ETHNICITY; GLUCOSE BLOOD LEVEL; GRAFT DYSFUNCTION; HEART MUSCLE ISCHEMIA; HEPATITIS C; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULINEMIA; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NONHUMAN; NUTRIENT; OBESITY; PANCREAS ISLET TRANSPLANTATION; REPERFUSION INJURY; RISK ASSESSMENT; SHORT SURVEY; SIDE EFFECT; ANIMAL; BLOOD; HISTOCOMPATIBILITY; MOUSE; NUDE MOUSE; REVIEW; SECRETION; XENOGRAFT;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, NUDE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

EID: 34247226008     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2006.11.002     Document Type: Short Survey

References (66)

1. Alejandro R., Feldman E.C., Bloom A.D., and Kenyon N.S. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 38 (1989) 698-703
2. Bell E., Cao X., Moibi J.A., et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52 (2003) 2731-2739
3. Bloom R.D., Rao V., Weng F., Grossman R.A., Cohen D., and Mange K.C. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J. Am. Soc. Nephrol. 13 (2002) 1374-1380
4. Boots J.M., Christiaans M.H., Van Duijnhoven E.M., Van Suylen R.J., and Van Hooff J.P. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 74 (2002) 1703-1709
5. Bussiere C.T., Lakey J.R., Shapiro A.M., and Korbutt G.S. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia (2006) (Ahead of print)
6. Chandrasekar B., and Mukherjee S.K. Effect of prolonged administration of cyclosporin A on (pro)insulin biosynthesis and insulin release by rat islets of Langerhans. Biochem. Pharmacol. 37 (1988) 3609-3611
7. Cosio F.G., Pesavento T.E., Osei K., Henry M.L., and Ferguson R.M. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 59 (2001) 732-737
8. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 75 10 suppl (2003) SS3-SS24
9. Dieterle C.D., Schmauss S., Veitenhansl M., et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. Transplantation 77 (2004) 1561-1565
10. Dmitrewski J., Krentz A.J., Mayer A.D., et al. Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation. Diabetes Obes. Metab. 3 (2001) 287-292
11. Dufer M., Krippeit-Drews P., Lembert N., Idahl L.A., and Drews G. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol. Pharmacol. 60 (2001) 873-879
12. Ebihara K., Fukunaga K., Matsumoto K., Shichiri M., and Miyamoto E. Cyclosporin A stimulation of glucose-induced insulin secretion in MIN6 cells. Endocrinology 137 (1996) 5255-5263
13. Egidi F.M. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?. Drugs 65 (2005) 153-166
14. Fabian M.C., Lakey J.R., Rajotte R.V., and Kneteman N.M. The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation 56 (1993) 1137-1142
15. Fuhrer D.K., Kobayashi M., and Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes. Metab. 3 (2001) 393-402
16. Gillison S.L., Bartlett S.T., and Curry D.L. Synthesis-secretion coupling of insulin. Effect of cyclosporin. Diabetes 38 (1989) 465-470
17. Gillison S.L., Bartlett S.T., and Curry D.L. Inhibition by cyclosporine of insulin secretion--a beta cell-specific alteration of islet tissue function. Transplantation 52 (1991) 890-895
18. Hahn H.J., Laube R., Lucke S., and Besch W. Alteration of pancreatic B-cells in Wistar rats treated with non-diabetogenic doses of cyclosporin A. Pharmacol. Toxicol. 70 (1992) 188-191
19. Hamaguchi K., Nakamura M., Ono J., and Takaki R. Ultrastructural and functional studies of pancreatic B cells in Wistar rats treated with immunotherapeutic doses of cyclosporin. Diabetes Res. Clin. Pract. 5 (1988) 135-143
20. Helmchen U., Schmidt W.E., Siegel E.G., and Creutzfeldt W. Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats. Diabetologia 27 (1984) 416-418
21. Herold K.C., Nagamatsu S., Buse J.B., Kulsakdinun P., and Steiner D.F. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation 55 (1993) 186-192
22. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 27 (2000) 6680-6686
23. Hjelmesaeth J., Ueland T., Flyvbjerg A., Bollerslev J., et al. Early post-transplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J. Am. Soc. Nephrol. 17 (2006) 1746-1754
24. Hirano Y., Hisatomi A., Ohara K., and Noguchi H. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. Transplantation 54 (1992) 883-887
25. Hirshberg B., Rother K.I., Digon III B.J., et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 26 (2003) 3288-3295
26. Hosoi H., Dilling M.B., Shikata T., et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 15 (1999) 886-894
27. Hui H., Khoury N., Zhao X., et al. Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 54 (2005) 424-433
28. Hyder A., Laue C., and Schrezenmeir J. Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categories. Toxicol. In Vitro 19 (2005) 541-546
29. Ikeuchi M., Kida K., Goto Y., Kaino Y., and Matsuda H. In vivo and in vitro effects of cyclosporin A on glucose transport by soleus muscles of mice. Biochem. Pharmacol. 43 (1992) 1459-1463
30. Ishizuka J., Gugliuzza K.K., Wassmuth Z., et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 56 (1993) 1486-1490
31. Kasiske B.L., Snyder J.J., Gilbertson D., and Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 3 (2003) 178-185
32. Kneteman N.M., Marchetti P., Tordjman K., et al. Effects of cyclosporine on insulin secretion and insulin sensitivity in dogs with intrasplenic islet autotransplants. Surgery 111 (1992) 430-437
33. Kneteman N.M., Lakey J.R., Wagner T., and Finegood D. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 61 (1996) 1206-1210
34. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
35. Konrad M., Steinmuller T., Vicini P., et al. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus. Transplantation 69 (2000) 2072-2078
36. Lopez-Talavera J.C., Garcia-Ocaña A., Sipula I., et al. Hepatocyte Growth Factor Gene Therapy for Pancreatic Islets in Diabetes: Reducing in the minimal Islet Transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 145 (2004) 467-474
37. Marcelli-Tourvieille T., Hubert E., Moerman F., et al. Sirolimus increases insulin secretion in vivo and in vitro at therapeutic concentrations. Transplantation (2007) (In press)
38. Menegazzo L.A., Ursich M.J., Fukui R.T., et al. Mechanism of the diabetogenic action of cyclosporin A. Horm. Metab. Res. 30 (1998) 663-667
39. Montori V.M., Basu A., Erwin P.J., Velosa J.A., Gabriel S.E., and Kudva Y.C. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25 (2002) 583-592
40. Mora P.F. Post-transplantation diabetes mellitus. Am. J. Med. Sci. 329 (2005) 86-94
41. Muthukkumar S., Ramesh T.M., and Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60 (1995) 264-270
42. Nielsen J.H., Mandrup-Poulsen T., and Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 35 (1986) 1049-1052
43. Pajvani U.B., Trujillo M.E., Combs T.P., et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat. Med. 11 (2005) 797-803
44. Paty B.W., Harmon J.S., Marsh C.L., and Robertson R.P. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 73 (2002) 353-357
45. Polastri L., Galbiati F., Bertuzzi F., et al. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol. 34 (2002) 229-233
46. Radu R.G., Fujimoto S., Mukai E., et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E365-E371
47. Redmon J.B., Olson L.K., Armstrong M.B., Greene M.J., and Robertson R.P. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J. Clin. Invest. 98 (1996) 2786-2793
48. Ricordi C., Zeng Y.J., Alejandro R., et al. In vivo effect of FK506 on human pancreatic islets. Transplantation 52 (1991) 519-522
49. Robertson R.P. Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes 35 (1986) 1016-1019
50. Robertson R.P., Franklin G., and Nelson L. Intravenous glucose tolerance and pancreatic islet beta-cell function in patients with multiple sclerosis during 2-yr treatment with cyclosporin. Diabetes 38 (1989) 58-64
51. Rostaing L., Cantarovich D., Mourad G., et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 79 (2005) 807-814
52. Ryan E.A., Paty W.B., Senior P.A., et al. Five-year follow-up after clinical islet transplantation. Diabetes 54 (2005) 2060-2069
53. Sato T., Inagaki A., Uchida K., et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 76 (2003) 1320-1326
54. Secchi A., Taglietti M.V., Socci C., et al. Insulin secretory patterns and blood glucose homeostasis after islet allotransplantation in IDDM patients: comparison with segmental- or whole-pancreas transplanted patients through a long-term longitudinal study. J. Mol. Med. 77 (1999) 133-139
55. Shi Y., Frankel A., Radvanyi L.G., et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1 (1995) 1982-1988
56. Strasser S., Alejandro R., Shapiro E.T., Ricordi C., Todo S., and Mintz D.H. Effect of FK506 on insulin secretion in normal dogs. Metabolism 41 (1992) 64-67
57. Strumph P., Kirsch D., Gooding W., and Carroll P. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. Transplantation 27 (1995) 147-151
58. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37 (1988) 1574-1582
59. Toyonaga T., Kondo T., Miyamura N., et al. Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus. Diabetes Res. Clin. Pract. 56 (2002) 13-18
60. Uchizono Y., Iwase M., Nakamura U., Sasaki N., Goto D., and Iida M. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 145 (2004) 2264-2272
61. Van Duijnhoven E.M., Christiaans M.H., Boots J.M., Nieman F.H., Wolffenbuttel B.H., and Van Hoof J.P. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J. Am. Soc. Nephrol. 13 (2002) 213-220
62. Wahlstrom H.E., Akimoto R., Endres D., Kolterman O., and Moossa A.R. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 53 (1992) 1190-1195
63. Wang Y., Li X., Zhao G., and Deng S. Short-term effects of cyclosporine A on the function of pancreatic islet cells in normal and spontaneous diabetic Chinese hamster. Sichuan Da Xue Xue Bao Yi Xue Ban 34 (2003) 552-554
64. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am. J. Transplant. 3 (2003) 590-598
65. Woltman A.M., De Fijter J.W., Kamerling S.W., et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98 (2001) 174-180
66. Zielinska T., Zakliczynski M., Szewczyk M., et al. Influence of long-term cyclosporine therapy on insulin and its precursors secretion in patients after heart transplantation. Ann. Transplant. 8 (2003) 10-12